Priaxon AG

Germany · Biotechnology

Priaxon AG drives small molecule drug R&D through the consequent early application of proprietary in silico methods to ligand interactions of interest, followed by the identification of pre-optimised modulators in novel chemical space. Focused hit-to-lead and lead optimisation stages allow rapid and cost effective generation of candidates with confirmed target interaction and target accessibility properties. As such, the Priaxon technology is truly target-focused and not constricted by proprietary target/class specific chemistry or assay technology. It is particularly suited for, but not limited to, the modulation of protein-protein interactions and allosteric sites. The Priaxon project pipeline focuses on Cancer/ Immunotherapy and Anti-infectives with novel modes of action.